# Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis

> **NCT07686042** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Autoimmune Encephalitis (AE)
- Autoimmune Cerebellitis

## Interventions

- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT07686042
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-24
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686042, "Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07686042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*